Eton Pharmaceuticals: An Undervalued Small Cap With High Growth

2026-01-23 10:20:07 ET

Article Thesis

I wrote about ETON Pharmaceuticals ( ETON ) at the beginning of August. I liked this company (and still do) because:

• They acquire ultra-rare disease drugs (aided by some internal development) at very low prices, and these are already FDA-approved or in a very advanced phase. This is possible because especially non-US companies are not interested in a market with a few hundred patients in the US.
• Their focused view on pediatric endocrinology and metabolics enables a highly targeted and efficient sales force.
• This focus on very small markets also helped them to diversify their portfolio and mitigate inherent risks that could appear for a single product.

Read the full article on Seeking Alpha

For further details see: